22 completed, 8 unknown, 6 terminated, 4 withdrawn. 44 Phase 2, 6 Phase 1, 4 Phase 3.
Follow Technical University of Munich: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) CD318-CAR-T cells - Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 38 | 2026-07-01 | 2025-09-03 |
| Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil - Metastatic Gastro-esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 126 | 2025-03-03 | 2026-01-07 |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] KEYTRUDA® - Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Leipzig | 140 | 2024-04-17 | 2024-09-20 |
| PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS) RAVICTI 1.1 g/ml, Placebo - Corticobasal Syndrome (CBS) | Phase 2 | Completed | Technical University of Munich | 32 | 2023-12-12 | 2026-09-11 |
| Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease Fasudil hydrochloride, Placebo - Idiopathic Parkinson´s Disease | Phase 2 | Completed | Technical University of Munich | 81 | 2023-09-11 | 2026-09-11 |
| Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy Mycophenolate Mofetil, Prednisolone, Mycophenolate Mofetil Placebo - Inflammatory Cardiomyopathy | Phase 2 / Phase 3 | Terminated | LMU Klinikum | 9 | 2023-03-28 | 2025-07-25 |
| Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW Bevacizumab-IRDye800CW - Breast Cancer | Phase 2 | Withdrawn | Technical University of Munich | 2021-06-01 | 2022-05-04 | |
| Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] - Nummular Eczema | Phase 2 | Active not recruiting | Technical University of Munich | 70 | 2021-03-30 | 2025-09-23 |
| Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation Alcon - Intracranial Tumor | Phase 2 | Completed | Technical University of Munich | 210 | 2020-12-30 | 2022-11-10 |
| Synaptic Plasticity and Cognitive Function in RASopathies Lovastatin, Lamotrigine - Impaired Synaptic Plasticity, Impaired Cognition | Phase 2 | Terminated | Technical University of Munich | 16 | 2019-03-22 | 2023-11-30 |
| Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder Nivolumab, Radiation therapy of the pelvis, Radical cystectomy with standardized pelvic lymphadenectomy - Urinary Bladder Cancer | Phase 2 | Unknown | Technical University of Munich | 33 | 2019-02-04 | 2022-10-20 |
| PINIT Study: Primary Intranasal Insulin Trial intranasal insulin, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Completed | Technical University of Munich | 38 | 2018-05-25 | 2021-06-22 |
| GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial) Oral Insulin, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Completed | Technical University of Munich | 1050 | 2018-02-07 | 2024-10-08 |
| Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept Revacept 80 mg, Revacept 160 mg, Placebo - Stable Coronary Artery Disease | Phase 2 | Completed | Deutsches Herzzentrum Muenchen | 334 | 2017-11-20 | 2020-04-20 |
| An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema Apremilast, Placebo Oral Tablet - Nummular Eczema, Eczema | Phase 2 | Completed | Technical University of Munich | 31 | 2017-07-05 | 2021-10-08 |
| Secretin Activates Human Brown Fat and Induces Satiation. Secretin Human, Saline Solution, Cold exposure - Obesity | Phase 2 / Phase 3 | Completed | Turku University Hospital | 23 | 2016-08-02 | 2019-12-23 |
| nTMS for Motor Mapping of Rolandic Lesions nTMS data available for the surgeon, nTMS data not available for the surgeon - Glioma, Brain Metastases | Phase 2 / Phase 3 | Completed | Technical University of Munich | 330 | 2016-08-01 | 2023-06-01 |
| Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Secukinumab - Pyoderma Gangrenosum | Phase 1 / Phase 2 | Completed | Technical University of Munich | 8 | 2016-04-01 | 2023-04-12 |
| RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial Radiotherapy, Needle Acupuncture - Cancer | Phase 2 | Unknown | Technical University of Munich | 74 | 2016-02-01 | 2016-02-04 |
| Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma SRT to the resection cavity - Glioblastoma | Phase 2 | Unknown | Technical University of Munich | 162 | 2016-02-01 | 2020-03-10 |
Showing 20 of 44. Sign in to see all of them.
Diabetes Mellitus (4) · Diabetes Mellitus, Type 1 (4) · Brain Neoplasms (2) · Breast Neoplasms (2) · Lymphoma (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Pancreatic Neoplasms (2) · Angioedema (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Pancreatic Ductal (1) · Cholangiocarcinoma (1) · Chromosome 17 deletion (1) · Cognition Disorders (1) · Coronary Artery Disease (1)
Neoadjuvant Therapy (4) · Oxaliplatin (4) · Insulin (3) · Radiotherapy (3) · Rituximab (3) · Chemotherapy, Adjuvant (2) · Cyclophosphamide (2) · Epirubicin (2) · Everolimus (2) · Fluorouracil (2) · Gemcitabine (2) · Paclitaxel (2) · Alemtuzumab (1) · Anastrozole (1) · Bi20 antibody (1)
Germany (40) · Austria (2) · Belgium (1) · Denmark (1) · Finland (1) · France (1) · Italy (1) · Poland (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Anette-G. Ziegler, Prof. Dr., MD (2) · Ezio Bonifacio, Prof. Dr., PhD (2) · Florian Lordick, MD (2) · Adnan Kastrati, MD (1) · Anette-G. Ziegler, Prof. Dr. (1) · Christian Peschel, MD (1) · Christiane Winkler, Dr., PhD (1) · F. Markus Leweke, MD (1) · Jens PD Gempt, MD (1) · Jens Siveke, Prof. Dr. (1) · Justus Prof. Duyster, MD (1) · Katharina Warncke, Dr., MD (1) · Kilian Eyerich (1) · Kilian Eyerich, MD, PhD (1)
PMID 34091488, PMID 23799873, PMID 23815981, PMID 25432532, PMID 25629740, PMID 26573139, PMID 28851420, PMID 29063805, PMID 29298660, PMID 31256036, PMID 31467127, PMID 31900121, PMID 33515070, PMID 33787834, PMID 34158656, PMID 34515338, PMID 34806426, PMID 36764966, PMID 37119871, PMID 37280688, PMID 38419648, PMID 39239277, PMID 40548467, PMID 41237794, PMID 42400090
2008 (1), 2016 (1), 2025 (1)